Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cuiyu Guo"'
Autor:
Guangbing Zhang, Cuiyu Guo, Yan Wang, Xianda Zhang, Shuang Liu, Wen Qu, Chunxia Chen, Lingli Yan, Zhouning Yang, Zhixiong Zhang, Xiaohua Jiang, Xiaofeng Chen, Hong Liu, Qinhuai Lai, Xian Wei, Ying Lu, Shengyan Zhao, Han Deng, Yuxi Wang, Lin Yu, Hongbin Yu, Yu Wu, Zhaoming Su, Pengyu Chen, Ziqing Ren, Meng Yu, Feng Qu, Yong Luo, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Anti-CD38 monoclonal antibodies (mAbs), daratumumab, and isatuximab have represented a breakthrough in the treatment of multiple myeloma (MM). Recently, CD38-based mAbs were expected to achieve increasing potential beyond MM, which encourage
Externí odkaz:
https://doaj.org/article/a39a57a1992548e1beadb485c54a357e
Autor:
Yiran Tao, Ruixue Wang, Qinhuai Lai, Mengdan Wu, Yuxi Wang, Xiaohua Jiang, Lishi Zeng, Shijie Zhou, Zhongping Li, Tinghan Yang, Yuqin Yao, Yangping Wu, Lin Yu, Yuyin Fu, Weirong Lai, Yujia Peng, Ying Lu, Zhixiong Zhang, Cuiyu Guo, Guangbing Zhang, Lantu Gou, Jinliang Yang
Publikováno v:
Molecular Oncology, Vol 13, Iss 9, Pp 1855-1873 (2019)
DDR1 has been identified as a cancer‐associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues. Clinically approved multi‐kinase inhibitors, such as nilotinib, inhibit DDR1‐mediated tumor gr
Externí odkaz:
https://doaj.org/article/8a0fb9edb8754179b4fc98f72579b623
Autor:
Shijie Zhou, Mengdan Wu, Yujia Peng, Lin Yu, Cuiyu Guo, Ruixue Wang, Lantu Gou, Weirong Lai, Ying Lu, Jinliang Yang, Tinghan Yang, Xiaohua Jiang, Yiran Tao, Guangbing Zhang, Yuxi Wang, Lishi Zeng, Yangping Wu, Qinhuai Lai, Zhongping Li, Zhixiong Zhang, Yuqin Yao, Yuyin Fu
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 13, Iss 9, Pp 1855-1873 (2019)
Molecular Oncology, Vol 13, Iss 9, Pp 1855-1873 (2019)
DDR1 has been identified as a cancer-associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues. Clinically approved multi-kinase inhibitors, such as nilotinib, inhibit DDR1-mediated tumor growth i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eab9aa8be424947df2d6c9eb3001929b
https://doi.org/10.1002/1878-0261.12520
https://doi.org/10.1002/1878-0261.12520
Autor:
Weirong Lai, Jamel Ali, Yiran Tao, Hanshuo Yang, Yuyin Fu, Yuqin Yao, E Dong, Ying Lu, Mengdan Wu, Jinliang Yang, Zhixiong Zhang, Lantu Gou, Guangbing Zhang, Yujia Peng, Cuiyu Guo, Qinhuai Lai, Shijie Zhou, Fanxin Ma, Xiaozhu Yue
Publikováno v:
MedComm
Ovarian cancer is considered to be the most lethal gynecologic malignancy, and despite the development of conventional therapies and new therapeutic approaches, the patient's survival time remains short because of tumor recurrence and metastasis. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fec0ce3e1434f5bc62710a35023789e
https://pubmed.ncbi.nlm.nih.gov/34766126
https://pubmed.ncbi.nlm.nih.gov/34766126
Autor:
Tai-Ran Kang, Weirong Lai, Xin Wang, Lantu Gou, Yiran Tao, Yuxi Wang, Lin Yu, Wei Liao, Qinhuai Lai, Ruixue Wang, Ruirui Zhang, Mengdan Wu, Jinliang Yang, Yiwen Zhang, Ying Lu, Zhixiong Zhang, Xiaohua Jiang, Hao Chen, Yujia Peng, Cuiyu Guo, Yuyin Fu, Yuqin Yao
Publikováno v:
European journal of medicinal chemistry. 199
Cryptophycin-52 (CR52), a tubulin inhibitor, exhibits promising antitumor activity in vitro (picomolar level) and in mouse xenograft models. However, the narrow therapeutic window in clinical trials limits its further development. Antibody-drug conju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23a9d4cb57a591554772bb62ed701f1b
https://pubmed.ncbi.nlm.nih.gov/32402935
https://pubmed.ncbi.nlm.nih.gov/32402935